Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SOMAÍ dried cannabis flower is a pharmaceutical-grade, EU-GMP certified medical cannabis product developed by SOMAÍ Pharmaceuticals. It consists of natural, unprocessed cannabis flowers sourced from selected cultivars grown in controlled indoor and greenhouse environments. The product contains a full spectrum of cannabinoids, primarily delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), which interact with the body's endocannabinoid system to provide therapeutic effects. Administered via inhalation (smoking or vaporization), it is designed for rapid onset of action, making it particularly effective for managing symptoms that require immediate relief. SOMAÍ expanded its production and distribution capabilities through the acquisition of RPK Biopharma (Holigen), ensuring a consistent supply of high-quality medical cannabis for international markets.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SOMAÍ dried cannabis flower.